By Professor Michael Leonard Friedlander

Conference Papers

Grimison PS; Stockler MR; Martin AJ; Buizen L; Lawrence NJ; Thomson DB; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2016, 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e16056

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei DE; Fielding A; Spencer S; Rowe P; Lowe ES; Matulonis UA, 2016, 'Overall survival (OS) in patients (pts) with platinum sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5501

Mileshkin LR; Edmondson RJ; O'Connell R; Sjoquist KM; Cannan D; Jyothirmayi R; Beale PJ; Bonaventura T; Goh JC; Hall M; Clamp AR; Green JA; Lord R; Scurry J; Friedlander M, 2016, 'Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial-ANZGOG 0903.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5520

Roncolato F; Gibbs E; Lee C; Davies LC; Gebski V; Friedlander M; Hilpert F; Wenzel LB; Stockler MR; King MT; Pujade-Lauraine E, 2016, 'Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5575

Lee YC; Milne RL; Smith C; Picken S; Camm S; McLachlan S-A; Friedlander M; Hopper JL; Phillips K-A, 2016, 'Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.1529

Grunewald T; Tang M; Chen J; Lord S; Friedlander M; Lee CK, 2016, 'Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5559

Hipert F; Friedlander M; Stockler M; O'Connell R; Joly F; Lanceley A; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; King M, 2016, 'Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3) - GCIG Symptom Benefit Study (AGO PRO1).', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, pp. 138 - 139, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000371353700449&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lawrence N; Toner G; Martin A; Stockler M; Yeung A; Wong N; Thomson D; Gebski V; Yip S; King M; Friedlander M; Quinn D; Tan TH; Chan H; Hanning F; Weickhardt A; Jeffery M; Stevanovic A; Hovey E; Wyld D; Davis I; Grimison P, 2015, 'A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS: THE P3BEP TRIAL (ANZUP 1302)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 146 - 147, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800237&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roncolato F; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; Stockler M; King M; Friedlander M; Kok P-S, 2015, 'BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING >= 3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 125 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; King MT, 2015, 'IS IT TIME TO CHANGE THE PRIMARY ENDPOINT IN CLINICAL TRIALS IN RECURRENT OVARIAN CANCER (ROC)? SYMPTOM BURDEN AND OUTCOMES IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE ROC RECEIVING >= 3 LINES OF CHEMOTHERAPY (PPS) - THE GYNECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 111 - 111, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800146&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Beale P; O'Connell R; Sjoquist K; Martyn J; Cannon D; Bonaventura T; Grant P; Goh J; Antill Y; Friedlander M; Scurry J, 2015, 'PARAGON-AN ANZGOG PHASE 2 STUDY OF ANASTRAZOLE IN ASYMPTOMATIC WOMEN WITH ESTROGEN (ER)/PROGESTERONE (PR) POSITIVE OVARIAN CANCER WITH A CA125 PROGRESSION AFTER FIRST LINE TREATMENT', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 118 - 118, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

King M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Buizen L; Sjoquist K; Butow P; Friedlander M; Gillies K; Martyn J, 2015, 'VALIDATION OF A PATIENT REPORTED OUTCOME MEASURE (PROM) OF OVARIAN CANCER SYMPTOMS AND TREATMENT RELATED CONCERNS (MOST-OSI) WITH CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC).', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 457 - 458, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145701081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

King M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Buizen L; Sjoquist K; Gillies K; Butow P; Friedlander M, 2015, 'Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 22 - 23, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361991100056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Huggins-Puhalla SL; Han HS; Dieras V; Friedlander M; Somlo G; Arun B; Wildiers H; Kaufman B; Ayoub J-PM; Shah M; Burmedi D; Qin Q; Qian J; Giranda VL; Shepherd SP, 2015, 'Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Breast Cancer Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 25 September 2015 - 27 September 2015, http://dx.doi.org/10.1200/jco.2015.33.28_suppl.155

Roncolato FT; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Butow P; Stockler MR; King MT; Friedlander M, 2015, 'Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5564

Lee C; Gibbs E; Roncolato FT; Davies LC; Le Maignan C; Meier W; Lanza MAA; Rosenberg P; Marchetti C; Vergote I; Witteveen P; Bamias A; Serra S; Provencal J; De Rauglaudre G; Gebski V; Friedlander M; Pujade-Lauraine E, 2015, 'Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5547

Phillips K-A; Collins IM; Milne RL; Fisher R; Stern C; Kannemeyer G; Smith C; Friedlander M; McLachlan S-A; Hickey M; Hopper JL, 2015, 'Do women with BRCA1 or BRCA2 mutations have reduced ovarian reserve?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.1537

Domchek SM; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmana J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B, 2015, 'Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5529

Matulonis U; Friedlander M; Du Bois A; Gourley C; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; McMurtry E; Spencer S; Mann H; Parry D; Ledermann JA, 2015, 'Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5550

Friedlander M; Stockler MR; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Butow P; King MT, 2015, 'Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5536

Debernardo R; Mahdi H; Russell K; Xiu J; Millis SZ; Reddy SK; Friedlander M, 2015, 'Molecular profile comparison of endometrial, renal and ovarian clear cell carcinoma: Is it the same disease at different sites?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5595

Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2015, 'Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5540

Puhalla S; Han HS; Dieras V; Friedlander M; Somlo G; Arun B; Wildiers H; Kaufman B; Ayoub J-PM; Shan M; Burmedi D; Qin Q; Qian J; Giranda VL; Shepherd SP, 2015, 'Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1102

Rafii S; Gourley C; Ang JE; Kumar R; Geuna E; Rye T; Ashcroft L; Powell B; Shapira-Frommer R; Friedlander M; Chen L-M; Matulonis U; Kaufman B; De Greve J; Oza AM; Banerjee SN; Gore ME; Molife LR; Kaye SB; Yap TA, 2015, 'What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5546

Segelov E, 2015, 'TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue', Chicago, presented at 2015 ASCO Annual Meeting, Chicago, 29 May 2015 - 02 June 2015

Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Fielding A; Spencer S; Parry D; Ledermann JA, 2015, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 8 - 8, http://dx.doi.org/10.1016/j.ygyno.2015.01.015

Banerjee S; Ledermann J; Matulonis U; Molife LR; Friedlander M; Fielding A; Robertson JD; Spencer S; McMurtry E; Kaye S, 2015, 'Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, pp. S550 - S550, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)31525-8

Wuttke M; Milne R; Weideman P; Picken S; Smith C; Friedlander M; McLachlan S-A; Hopper JL; Phillips K-A, 2014, 'Breast cancer screening by women from BRCA1 & BRCA2 mutation positive families', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2014 - 13 December 2014, http://dx.doi.org/10.1158/1538-7445.SABCS14-P3-02-03

Mileshkin L; Sjoquist KM; Sommeijer DW; Cannan D; Martyn J; Gillies K; O'Connell R; Gebski V; Sykes P; Blomfield P; Beale P; Quinn M; Lombard J; Hadley A; Grant P; Antill Y; Stockler M; Amant F; Edmondson RJ; Friedlander M, 2014, 'PARAGON- PHASE II STUDY OF AROMATASE INHIBITORS IN WOMEN WITH POTENTIALLY HORMONE RESPONSIVE RECURRENT/METASTATIC GYNAECOLOGICAL NEOPLASMS: ANZGOG 0903', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 167 - 167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML, 2014, 'A new patient-reported outcome measure for symptom benefit with chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 20 - 20, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lheureux S; Ledermann J; Kaye S; Gourley C; Friedlander M; Bowtell D; De Greve J; DeFazio A; Frommer R; De Bono JS; Audeh MW; Kohn E; Alsop K; Scott C; Matulonis U; Kaufman B; Burger B; Robertson J; Ho T; Oza A, 2014, 'A PILOT INTEGRATED ANALYSIS OF LONG-TERM BENEFIT OF OLAPARIB IN OVARIAN CANCER: RESULTS OF FEASIBILITY TESTING.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 141 - 142, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; King K; Stinnett S; Barrett C; Jobanputra M; Chun-Fang X; du Bois A, 2014, 'BRCA1/2 MUTATIONS ASSOCIATED WITH PROGRESSION FREE SURVIVAL IN OVARIAN CANCER PATIENTS WHO RECEIVED PAZOPANIB OR PLACEBO IN THE AGO-OVAR16 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2014, 'COMPARISON OF OVARIAN AND RENAL CLEAR CELL CARCINOMA BY COMPREHENSIVE TUMOR PROFILING', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 148 - 148, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500123&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Inglis H; Boyle F; Friedlander M; Watson S, 2014, 'DRY EYES & AIS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 33 - 33, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Inglis H; Boyle F; Friedlander M; Watson S, 2014, 'DRY EYES & AIS', in CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, WILEY-BLACKWELL, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344530600094&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ryland G; Hadley A; Wakefield M; Hunter S; Antill Y; Ananda S; Bae S; Lipton L; Boussioutas A; Friedlander M; Liauw W; Fox S; DeFazio A; Bowtell D; Christie M; Pyman J; Scott C; Campbell I; Gorringe K, 2014, 'GAMUT - GENOMIC ANALYSIS OF MUCINOUS TUMOURS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 129 - 130, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500110&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hadley AM; Ryland G; Christie M; Antill Y; Bae S; Hunter S; Lipton L; Boussioutas A; Bowtell D; Jobling T; Friedlander M; Fox S; DeFazio A; Wakefield M; Campbell I; Gorringe K; Pyman J; Scott CL; Ananda S, 2014, 'HIGH-GRADE MUCINOUS OVARIAN CANCER: CLINICAL AND MOLECULAR ANNOTATION OF A RARE CANCER, ORIGINS AND THERAPEUTIC POTENTIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 426 - 427, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500300&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wuttke M; Milne R; Weideman P; Picken S; Smith C; Friedlander M; McLachlan S; Hopper JL; Phillips K, 2014, 'OVARIAN CANCER SCREENING BY AUSTRALIAN WOMEN FROM FAMILIES WITH BRCA1 OR BRCA2 MUTATIONS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 223 - 224, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Sjoquist KM; Beale P; Sommeijer DW; Mileshkin L; Martyn J; McNally O; O'Connell R; Grant P; Hadley A; Gillies K; Goh J; Bonaventura A, 2014, 'PARAGON (ANZGOG0903): PHASE 2 STUDY OF ANASTROZOLE IN WOMEN WITH ESTROGEN(ER)/PROGESTERONE (PR) POSITIVE PLATINUM RESISTANT/REFRACTORY RECURRENT OVARIAN CANCER (PRROC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 38 - 38, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sousa M; Meiser B; Hickey M; Jarvis S; Lombard J; Chirgwin J; Segelov E; Friedlander M, 2014, 'PEGASUS - Prevalence and severity of genitourinary symptoms and impact on sexual function and quality of life in postmenopausal women receiving adjuvant endocrine therapy for early stage breast cancer - A prospective study', in MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, LIPPINCOTT WILLIAMS & WILKINS, DC, Washington, pp. 1364 - 1364, presented at 25th Annual Meeting of the North-American-Menopause-Society, DC, Washington, 15 October 2014 - 18 October 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345846600165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mileshkin LR; Narayan K; Moore KN; Rischin D; King M; Kolodziej I; Marlyn J; Friedlander M; Quinn M; Small W; Thomas G; Fyles AW; Gebski V; Stockier MR, 2014, 'A phase III trial of adjuvant chemotherapy following chemoradialion as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/G0G0274/RTOG1174).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358613202170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lheureux S; Ledermann JA; Kaye SB; Gourley C; Friedlander M; Bowtell D; De Greve J; deFazio A; Shapira-Frommer R; De Bono JS; Audeh MW; Kohn EC; Alsop K; Scott CL; Matulonis U; Kaufman B; Burger B; Robertson JD; Ho T; Oza AM, 2014, 'Characterization of ovarian cancer long-term responders on olaparib.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5534

Friedlander M; Stockier MR; Butow PN; Oza AM; O'Connell R; Martyn J; Glilles K; Sjoquist KM; King M, 2014, 'Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5615

Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2014, 'Molecular profiling of clear cell ovarian carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5516

Sjoquist KM; Sommelier DW; Lombard JM; Mileshkin LR; Beale PJ; Grant PT; Blomfield P; Quinn M; Hadley AM; Sykes P; Antill YC; O'Connell R; Martyn J; Gillies K; Cannan D; Gebski V; Stockier MR; Edmondson RJ; Amant F; Friedlander M, 2014, 'The PARAGON phase 2 trial of anastrozole us women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5621

Sjoquist KM; Friedlander M; Mileshkin LR; Quinn M; Goh JC; Shannon CM; Bovdell D; Plebanskl M; Yip S; Canton K; Gillies K; Martyn J; Gebski V, 2014, 'The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab no patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5627

Inglis H; Friedlander M; Watson SL, 2014, 'Dry Eyes and AIs', in INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433199700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Long A; Sommeijer D; Roncolato F; King M; Brundage M; Stockler M; Friedlander M, 2014, 'QUALITY OF REPORTING OF PATIENT RATED OUTCOMES IN OVARIAN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEW', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 61 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Long A; Toner GC; Stockler M; Thompson DB; Gebski V; Yip S; King M; Friedlander M; Quinn D; Singhal N; Roncolato F; Grimison PS, 2014, 'THE ANZUP PHASE 3 ACCELERATED BEP TRIAL: A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 61 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandler C; Webber K; Friedlander M; Lewis C; Chin M; Venkateswaran R; Segelov E; Bastick P; Lynch J; Thomas D; Liauw W; Boyle F; Goldstein D; Lloyd A, 2013, 'BARRIERS TO RECRUITMENT FOR A POST-CANCER FATIGUE INTERVENTION STUDY - THE TOPS TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 116 - 116, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page